CN Patent

CN107652289B — 作为fgfr抑制剂的取代的三环化合物

Assigned to Incyte Corp · Expires 2020-07-21 · 6y expired

What this patent protects

本发明涉及作为一种或多种FGFR酶的抑制剂且适用于治疗FGFR相关的疾病如癌症的式I三环化合物和所述式I三环化合物的药物组合物。

USPTO Abstract

本发明涉及作为一种或多种FGFR酶的抑制剂且适用于治疗FGFR相关的疾病如癌症的式I三环化合物和所述式I三环化合物的药物组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN107652289B
Jurisdiction
CN
Classification
—
Expires
2020-07-21
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.